Clinical management of HIV-associated hematologic malignancies

References

• Schneider E, Whitmore S, Glynn KM, et al. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years–United States, 2008. MMWR Recomm Rep. 2008;57:1–12.
   PubMedGoogle Scholar
• Simard EP, Pfeiffer RM, Engels EA. Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. Cancer. 2011;117:1089–1096.
   PubMed Web of Science ®Google Scholar
• Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005;97:425–432.
   PubMed Web of Science ®Google Scholar
• Bohlius J, Schmidlin K, Boue F, et al. HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4(+) T-cell lymphocytes. Blood. 2011;117:6100–6108.
   PubMed Web of Science ®Google Scholar
• Calabresi A, Ferraresi A, Festa A, et al. Incidence of AIDS-defining cancers and virus-related and non-virus-related non-AIDS-defining cancers among HIV-infected patients compared with the general population in a large health district of Northern Italy, 1999-2009. HIV Med. 2013;14:481–490.
   PubMed Web of Science ®Google Scholar
• Shiels MS, Koritzinsky EH, Clarke CA, et al. Prevalence of HIV Infection among U.S. Hodgkin lymphoma cases. Cancer Epidemiol Biomarkers Prev. 2014;23:274–281.
   PubMed Web of Science ®Google Scholar
• Shiels MS, Pfeiffer RM, Engels EA. Age at cancer diagnosis among persons with AIDS in the United States. Ann Intern Med. 2010;153:452–460.
   PubMed Web of Science ®Google Scholar
• Besson C, Goubar A, Gabarre J, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood. 2001;98:2339–2344.
   PubMed Web of Science ®Google Scholar
• Robbins HA, Shiels MS, Pfeiffer RM, et al. Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States. Aids. 2014;28:881–890.
   PubMed Web of Science ®Google Scholar
• Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011;103:753–762.
   PubMed Web of Science ®Google Scholar
• Hoffmann C, Hentrich M, Gillor D, et al. Hodgkin lymphoma is as common as non-Hodgkin lymphoma in HIV-positive patients with sustained viral suppression and limited immune deficiency: a prospective cohort study. HIV Med. 2015;16:261–264.
   PubMed Web of Science ®Google Scholar
• Frisch M, Biggar RJ, Engels EA, et al., Group AI-CMRS. Association of cancer with AIDS-related immunosuppression in adults. Jama. 2001;285:1736–1745.
   PubMed Web of Science ®Google Scholar
• Grulich AE, Li Y, McDonald A, et al. Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. Aids. 2002;16:1155–1161.
   PubMed Web of Science ®Google Scholar
• Hoffmann C, Chow KU, Wolf E, et al. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin’s disease. Br J Haematol. 2004;125:455–462.
   PubMed Web of Science ®Google Scholar
• Clayton A, Mughal T. The changing face of HIV-associated lymphoma: what can we learn about optimal therapy inl the post highly active antiretroviral therapy era? Hematol Oncol. 2004;22:111–120.
   PubMed Web of Science ®Google Scholar
• Lanoy E, Rosenberg PS, Fily F, et al. HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy. Blood. 2011;118:44–49.
   PubMed Web of Science ®Google Scholar
• Bohlius J, Schmidlin K, et al., Collaboration of Observational HIVEREsg. Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. Aids. 2009;23:2029–2037.
   PubMed Web of Science ®Google Scholar
• Little RF, Dunleavy K. Update on the treatment of HIV-associated hematologic malignancies. Hematology Am Soc Hematol Educ Program. 2013;2013:382–388.
   PubMedGoogle Scholar
• Gopal S, Patel MR, Yanik EL, et al. Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst. 2013;105:1221–1229.
   PubMed Web of Science ®Google Scholar
• Barta SK, Lee JY, Kaplan LD, et al. Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma. Cancer. 2012;118:3977–3983.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Little RF, Pittaluga S, et al. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood. 2010;115:3017–3024.
   PubMed Web of Science ®Google Scholar
• Chao C, Xu L, Abrams D, et al. Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy. Aids. 2010;24:1765–1770.
   PubMed Web of Science ®Google Scholar
• The Non-Hodgkin’s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood. 1997;89:3909–3918.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–282.
   PubMed Web of Science ®Google Scholar
• Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood. 2011;117:2319–2331.
   PubMed Web of Science ®Google Scholar
• Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010;28:3360–3365.
   PubMed Web of Science ®Google Scholar
• Le Gouill S, Talmant P, Touzeau C, et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica. 2007;92:1335–1342.
   PubMed Web of Science ®Google Scholar
• Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114:3533–3537.
   PubMed Web of Science ®Google Scholar
• Snuderl M, Kolman OK, Chen YB, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol. 2010;34:327–340.
   PubMed Web of Science ®Google Scholar
• Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30:3460–3467.
   PubMed Web of Science ®Google Scholar
• Hoffmann C, Tiemann M, Schrader C, et al. AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping. Blood. 2005;106:1762–1769.
   PubMed Web of Science ®Google Scholar
• Chadburn A, Chiu A, Lee JY, et al. Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. J Clin Oncol. 2009;27:5039–5048.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121–3127.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–391.
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23:4117–4126.
   PubMed Web of Science ®Google Scholar
• Ratner L, Lee J, Tang S, et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin’s lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol. 2001;19:2171–2178.
   PubMed Web of Science ®Google Scholar
• Weiss R, Mitrou P, Arasteh K, et al. Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival–results of the German Multicenter Trial. Cancer. 2006;106:1560–1568.
   PubMed Web of Science ®Google Scholar
• Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005;106:1538–1543.
   PubMed Web of Science ®Google Scholar
• Boue F, Gabarre J, Gisselbrecht C, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin’s lymphoma. J Clin Oncol. 2006;24:4123–4128.
   PubMed Web of Science ®Google Scholar
• Ribera JM, Oriol A, Morgades M, et al. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol. 2008;140:411–419.
   PubMed Web of Science ®Google Scholar
• Sparano JA, Lee JY, Kaplan LD, et al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood. 2010;115:3008–3016.
   PubMed Web of Science ®Google Scholar
• Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood. 2003;101:4653–4659.
   PubMed Web of Science ®Google Scholar
• Barta SK, Xue X, Wang D, et al. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood. 2013;122:3251–3262.
   PubMed Web of Science ®Google Scholar
• Krishnan A, Molina A, Zaia J, et al. Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood. 2005;105:874–878.
   PubMed Web of Science ®Google Scholar
• Spitzer TR, Ambinder RF, Lee JY, et al. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant. 2008;14:59–66.
   PubMed Web of Science ®Google Scholar
• Re A, Michieli M, Casari S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood. 2009;114:1306–1313.
   PubMed Web of Science ®Google Scholar
• Serrano D, Carrion R, Balsalobre P, et al. HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation. Exp Hematol. 2005;33:487–494.
   PubMed Web of Science ®Google Scholar
• Alvarnas J, Le Rademacher J, Wang Y, et al. Blood and Marrow Transplant Clinical Trials Network (BMT CTN) and The AIDS Malignancy Consortium, (AMC). Autologous Hematopoietic Stem Cell Transplantation (AHCT) in Patients with Chemotherapy-Sensitive, Relapsed/Refractory (CSRR) Human Immunodeficiency Virus (HIV)-Associated Lymphoma (HAL): results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0803)/AIDS Malignancy Consortium (AMC-071) Trial. 56th ASH Annual Meeting. 2014; San Francisco, CA.
   Google Scholar
• Balsalobre P, Diez-Martin JL, Re A, et al. Autologous stem-cell transplantation in patients with HIV-related lymphoma. J Clin Oncol. 2009;27:2192–2198.
   PubMed Web of Science ®Google Scholar
• Schooley RT, Mladenovic J, Sevin A, et al. Reduced mobilization of CD34+ stem cells in advanced human immunodeficiency virus type 1 disease. J Infect Dis. 2000;181:148–157.
   PubMed Web of Science ®Google Scholar
• Sloand EM, Young NS, Sato T, et al. Secondary colony formation after long-term bone marrow culture using peripheral blood and bone marrow of HIV-infected patients. Aids. 1997;11:1547–1553.
   PubMed Web of Science ®Google Scholar
• Zauli G, Capitani S. HIV-1-related mechanisms of suppression of CD34+ hematopoietic progenitors. Pathobiology. 1996;64:53–58.
   PubMed Web of Science ®Google Scholar
• Re A, Cattaneo C, Skert C, et al. Stem cell mobilization in HIV seropositive patients with lymphoma. Haematologica. 2013;98:1762–1768.
   PubMed Web of Science ®Google Scholar
• Bayraktar UD, Ramos JC, Petrich A, et al. Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy Consortium. Leuk Lymphoma. 2012;53:2383–2389.
   PubMed Web of Science ®Google Scholar
• Gibson TM, Morton LM, Shiels MS, et al. Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study. Aids. 2014;28:2313–2318.
   PubMedGoogle Scholar
• Davi F, Delecluse HJ, Guiet P, et al. Burkitt-like lymphomas in AIDS patients: characterization within a series of 103 human immunodeficiency virus-associated non-Hodgkin’s lymphomas. Burkitt’s Lymphoma Study Group. J Clin Oncol. 1998;16:3788–3795.
   PubMed Web of Science ®Google Scholar
• Spina M, Tirelli U, Zagonel V, et al. Burkitt’s lymphoma in adults with and without human immunodeficiency virus infection: a single-institution clinicopathologic study of 75 patients. Cancer. 1998;82:766–774.
   PubMed Web of Science ®Google Scholar
• Ostronoff M, Soussain C, Zambon E, et al. Burkitt’s lymphoma in adults: a retrospective study of 46 cases. Nouv Rev Fr Hematol. 1992;34:389–397.
   PubMedGoogle Scholar
• Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996;14:925–934.
   PubMed Web of Science ®Google Scholar
• Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol. 2002;13:1264–1274.
   PubMed Web of Science ®Google Scholar
• Cortes J, Thomas D, Rios A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer. 2002;94:1492–1499.
   PubMed Web of Science ®Google Scholar
• Thomas DA, Cortes J, O’Brien S, et al. Hyper-CVAD program in Burkitt’s-type adult acute lymphoblastic leukemia. J Clin Oncol. 1999;17:2461–2470.
   PubMed Web of Science ®Google Scholar
• Lim ST, Karim R, Tulpule A, et al. Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy. J Clin Oncol. 2005;23:8477–8482.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt’s lymphoma. N Engl J Med. 2013;369:1915–1925.
   PubMed Web of Science ®Google Scholar
• Wang ES, Straus DJ, Teruya-Feldstein J, et al. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer. 2003;98:1196–1205.
   PubMed Web of Science ®Google Scholar
• Noy A, Lee JY, Cesarman E, et al. AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma. Blood. 2015;126:160–166.
   PubMed Web of Science ®Google Scholar
• Dolecek TA, Propp JM, Stroup NE, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol. 2012;14(Suppl 5):v1–49.
   PubMed Web of Science ®Google Scholar
• Panageas KS, Elkin EB, DeAngelis LM, et al. Trends in survival from primary central nervous system lymphoma, 1975-1999: a population-based analysis. Cancer. 2005;104:2466–2472.
   PubMed Web of Science ®Google Scholar
• Inungu J, Melendez MF, Montgomery JP. AIDS-related primary brain lymphoma in Michigan, January 1990 to December 2000. AIDS Patient Care STDS. 2002;16:107–112.
   PubMed Web of Science ®Google Scholar
• Schabet M. Epidemiology of primary CNS lymphoma. J Neurooncol. 1999;43:199–201.
   PubMed Web of Science ®Google Scholar
• Wang CC, Carnevale J, Rubenstein JL. Progress in central nervous system lymphomas. Br J Haematol. 2014;166:311–325.
   PubMed Web of Science ®Google Scholar
• Nelson DF, Martz KL, Bonner H, et al. Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys. 1992;23:9–17.
   PubMed Web of Science ®Google Scholar
• Blay JY, Conroy T, Chevreau C, et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol. 1998;16:864–871.
   PubMed Web of Science ®Google Scholar
• Gavrilovic IT, Hormigo A, Yahalom J, et al. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2006;24:4570–4574.
   PubMed Web of Science ®Google Scholar
• Skarin AT, Zuckerman KS, Pitman SW, et al. High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin lymphoma including CNS involvement. Blood. 1977;50:1039–1047.
   PubMed Web of Science ®Google Scholar
• Zhu JJ, Gerstner ER, Engler DA, et al. High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro Oncol. 2009;11:211–215.
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Hsi ED, Johnson JL, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. 2013;31:3061–3068.
   PubMed Web of Science ®Google Scholar
• DeAngelis LM, Seiferheld W, Schold SC, et al. Radiation Therapy Oncology Group S. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol. 2002;20:4643–4648.
   PubMed Web of Science ®Google Scholar
• Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010;11:1036–1047.
   PubMed Web of Science ®Google Scholar
• Illerhaus G, Muller F, Feuerhake F, et al. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica. 2008;93:147–148.
   PubMed Web of Science ®Google Scholar
• Bayraktar S, Bayraktar UD, Ramos JC, et al. Primary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors. J Neurooncol. 2011;101:257–265.
   PubMed Web of Science ®Google Scholar
• Gupta NK, Hwang J, Rubenstein JL High-Dose Methotrexate Is Effective, Safe, and Leads To Durable Responses In Patients With AIDS-Related Primary Central Nervous System Lymphoma Treated During The Era Of Combined Anti-Retroviral Therapy. American Society of Hematology Annual Meeting. 2013; New Orleans, LA.
   Google Scholar
• O’Neill A, Mikesch K, Fritsch K, et al. Outcomes for HIV-positive patients with primary central nervous system lymphoma after high-dose chemotherapy and auto-SCT. Bone Marrow Transplant. 2015;50:999–1000.
   PubMed Web of Science ®Google Scholar
• Wolf T, Kiderlen T, Atta J, et al. Successful treatment of AIDS-associated, primary CNS lymphoma with rituximab- and methotrexate-based chemotherapy and autologous stem cell transplantation. Infection. 2014;42:445–447.
   PubMed Web of Science ®Google Scholar
• Riedel DJ, Gonzalez-Cuyar LF, Zhao XF, et al. Plasmablastic lymphoma of the oral cavity: a rapidly progressive lymphoma associated with HIV infection. Lancet Infect Dis. 2008;8:261–267.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Winer ES, Stachurski D, et al. Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma. Leuk Lymphoma. 2010;51:2047–2053.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Winer ES, Stachurski D, et al. Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma. Oncologist. 2010;15:293–299.
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Re A, Ungari M, et al. Plasmablastic lymphoma among human immunodeficiency virus-positive patients: results of a single center’s experience. Leuk Lymphoma. 2015;56:267–269.
   PubMed Web of Science ®Google Scholar
• Teruya-Feldstein J, Chiao E, Filippa DA, et al. CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogenous spectrum in both HIV-positive and -negative patients. Ann Oncol. 2004;15:1673–1679.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Furman M, Beltran BE, et al. Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy. Cancer. 2012;118:5270–5277.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Pittaluga S, Czuczman MS, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 2009;113:6069–6076.
   PubMed Web of Science ®Google Scholar
• Bibas M, Grisetti S, Alba L, et al. Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone. J Clin Oncol. 2010;28:e704–8.
   PubMed Web of Science ®Google Scholar
• Yan M, Dong Z, Zhao F, et al. CD20-positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab. Eur J Haematol. 2014;93:77–80.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Reagan JL, Sikov WM, et al. Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma. Br J Haematol. 2015;169:352–355.
   PubMed Web of Science ®Google Scholar
• Holderness BM, Malhotra S, Levy NB, et al. Brentuximab vedotin demonstrates activity in a patient with plasmablastic lymphoma arising from a background of chronic lymphocytic leukemia. J Clin Oncol. 2013;31:e197–9.
   PubMed Web of Science ®Google Scholar
• Sarode SC, Zarkar GA, Desai RS, et al. Plasmablastic lymphoma of the oral cavity in an HIV-positive patient: a case report and review of literature. Int J Oral Maxillofac Surg. 2009;38:993–999.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Blood. 2015;125:2323–2330.
   PubMed Web of Science ®Google Scholar
• Chen YB, Rahemtullah A, Hochberg E. Primary effusion lymphoma. Oncologist. 2007;12:569–576.
   PubMed Web of Science ®Google Scholar
• Dukers NH, Rezza G. Human herpesvirus 8 epidemiology: what we do and do not know. Aids. 2003;17:1717–1730.
   PubMed Web of Science ®Google Scholar
• Nador RG, Cesarman E, Chadburn A, et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi’s sarcoma-associated herpes virus. Blood. 1996;88:645–656.
   PubMed Web of Science ®Google Scholar
• Simonelli C, Spina M, Cinelli R, et al. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. J Clin Oncol. 2003;21:3948–3954.
   PubMed Web of Science ®Google Scholar
• Boulanger E, Gerard L, Gabarre J, et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol. 2005;23:4372–4380.
   PubMed Web of Science ®Google Scholar
• Hocqueloux L, Agbalika F, Oksenhendler E, et al. Long-term remission of an AIDS-related primary effusion lymphoma with antiviral therapy. Aids. 2001;15:280–282.
   PubMed Web of Science ®Google Scholar
• Oksenhendler E, Clauvel J-P, Jouveshomme S, et al. Complete remission of a primary effusion lymphoma with antiretroviral therapy. Am J Hematol. 1998;57:266.
   PubMed Web of Science ®Google Scholar
• Waddington TW, Aboulafia DM. Failure to eradicate AIDS-associated primary effusion lymphoma with high-dose chemotherapy and autologous stem cell reinfusion: case report and literature review. AIDS Patient Care STDS. 2004;18:67–73.
   PubMed Web of Science ®Google Scholar
• Won JH, Han SH, Bae SB, et al. Successful eradication of relapsed primary effusion lymphoma with high-dose chemotherapy and autologous stem cell transplantation in a patient seronegative for human immunodeficiency virus. Int J Hematol. 2006;83:328–330.
   PubMed Web of Science ®Google Scholar
• Halfdanarson TR, Markovic SN, Kalokhe U, et al. A non-chemotherapy treatment of a primary effusion lymphoma: durable remission after intracavitary cidofovir in HIV negative PEL refractory to chemotherapy. Ann Oncol. 2006;17:1849–1850.
   PubMed Web of Science ®Google Scholar
• Luppi M, Trovato R, Barozzi P, et al. Treatment of herpesvirus associated primary effusion lymphoma with intracavity cidofovir. Leukemia. 2005;19:473–476.
   PubMed Web of Science ®Google Scholar
• Ozbalak M, Tokatli I, Ozdemirli M, et al. Is valganciclovir really effective in primary effusion lymphoma: case report of an HIV(-) EBV(-) HHV8(+) patient. Eur J Haematol. 2013;91:467–469.
   PubMed Web of Science ®Google Scholar
• An J, Sun Y, Fisher M, et al. Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia. 2004;18:1699–1704.
   PubMed Web of Science ®Google Scholar
• Matta H, Chaudhary PM. The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells. Cancer Biol Ther. 2005;4:77–82.
   PubMed Web of Science ®Google Scholar
• Boulanger E, Meignin V, Oksenhendler E. Bortezomib (PS-341) in patients with human herpesvirus 8-associated primary effusion lymphoma. Br J Haematol. 2008;141:559–561.
   PubMed Web of Science ®Google Scholar
• Bhatt S, Ashlock BM, Toomey NL, et al. Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma. J Clin Invest. 2013;123:2616–2628.
   PubMed Web of Science ®Google Scholar
• Tirelli U, Errante D, Dolcetti R, et al. Hodgkin’s disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors. J Clin Oncol. 1995;13:1758–1767.
   PubMed Web of Science ®Google Scholar
• Errante D, Tirelli U, Gastaldi R, et al. Combined antineoplastic and antiretroviral therapy for patients with Hodgkin’s disease and human immunodeficiency virus infection. A prospective study of 17 patients. The Italian Cooperative Group on AIDS and Tumors (GICAT). Cancer. 1994;73:437–444.
   PubMed Web of Science ®Google Scholar
• Levine AM, Li P, Cheung T, et al. Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin’s disease: a prospective, multi-institutional AIDS clinical trials group study (ACTG 149). J Acquir Immune Defic Syndr. 2000;24:444–450.
   PubMed Web of Science ®Google Scholar
• Montoto S, Shaw K, Okosun J, et al. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol. 2012;30:4111–4116.
   PubMed Web of Science ®Google Scholar
• Hentrich M, Berger M, Wyen C, et al. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. J Clin Oncol. 2012;30:4117–4123.
   PubMed Web of Science ®Google Scholar
• Uldrick TS, Little RF. How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus. Blood. 2015;125:1226–1235. quiz 355.
   PubMed Web of Science ®Google Scholar
• Boleti E, Mead GM. ABVD for Hodgkin’s lymphoma: full-dose chemotherapy without dose reductions or growth factors. Ann Oncol. 2007;18:376–380.
   PubMed Web of Science ®Google Scholar
• Martin WG, Ristow KM, Habermann TM, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol. 2005;23:7614–7620.
   PubMed Web of Science ®Google Scholar
• Saxman SB, Nichols CR, Einhorn LH. Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor. Chest. 1997;111:657–660.
   PubMed Web of Science ®Google Scholar
• Younes A, Fayad L, Romaguera J, et al. Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma. Eur J Cancer. 2006;42:2976–2981.
   PubMed Web of Science ®Google Scholar
• Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30:2183–2189.
   PubMed Web of Science ®Google Scholar
• Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma. ClinicalTrials.gov. [ cited 2015 Jul 31. Available from: https://clinicaltrials.gov/show/NCT01771107.
   Google Scholar
• Stebbing J, Pantanowitz L, Dayyani F, et al. HIV-associated multicentric Castleman’s disease. Am J Hematol. 2008;83:498–503.
   PubMed Web of Science ®Google Scholar
• Kaplan LD. Human herpesvirus-8: Kaposi sarcoma, multicentric Castleman disease, and primary effusion lymphoma. Hematology Am Soc Hematol Educ Program. 2013;2013:103–108.
   PubMed Web of Science ®Google Scholar
• Mylona EE, Baraboutis IG, Lekakis LJ, et al. Multicentric Castleman’s disease in HIV infection: a systematic review of the literature. AIDS Rev. 2008;10:25–35.
   PubMed Web of Science ®Google Scholar
• Andhavarapu S, Jiang L. POEMS syndrome and Castleman disease. Blood. 2013;122:159.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A. POEMS syndrome: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol. 2011;86:591–601.
   PubMed Web of Science ®Google Scholar
• Oksenhendler E, Duarte M, Soulier J, et al. Multicentric Castleman’s disease in HIV infection: a clinical and pathological study of 20 patients. Aids. 1996;10:61–67.
   PubMed Web of Science ®Google Scholar
• Bower M, Newsom-Davis T, Naresh K, et al. Clinical Features and Outcome in HIV-Associated Multicentric Castleman’s Disease. J Clin Oncol. 2011;29:2481–2486.
   PubMed Web of Science ®Google Scholar
• Soumerai JD, Sohani AR, Abramson JS. Diagnosis and management of Castleman disease. Cancer Control. 2014;21:266–278.
   PubMed Web of Science ®Google Scholar
• Carbone A, De Paoli P, Gloghini A, et al. KSHV-associated multicentric Castleman disease: A tangle of different entities requiring multitarget treatment strategies. Int J Cancer. 2015;137:251–261.
   PubMed Web of Science ®Google Scholar
• Powles T, Stebbing J, Bazeos A, et al. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman’s disease. Ann Oncol. 2009;20:775–779.
   PubMed Web of Science ®Google Scholar
• Aaron L, Lidove O, Yousry C, et al. Human herpesvirus 8-positive Castleman disease in human immunodeficiency virus-infected patients: the impact of highly active antiretroviral therapy. Clin Infect Dis. 2002;35:880–882.
   PubMed Web of Science ®Google Scholar
• Sprinz E, Jeffman M, Liedke P, et al. Successful treatment of AIDS-related Castleman’s disease following the administration of highly active antiretroviral therapy (HAART). Ann Oncol. 2004;15:356–358.
   PubMed Web of Science ®Google Scholar
• Lee SM, Edwards SG, Chilton DN, et al. Highly active antiretroviral therapy alone may be an effective treatment for HIV-associated multi-centric Castleman’s disease. Haematologica. 2010;95:1979–1981.
   PubMed Web of Science ®Google Scholar
• Herrada J, Cabanillas F, Rice L, et al. The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med. 1998;128:657–662.
   PubMed Web of Science ®Google Scholar
• Seo HY, Kim EB, Kim JW, et al. Complete remission in a patient with human herpes virus-8 negative multicentric Castleman disease using CHOP chemotherapy. Cancer Res Treat. 2009;41:104–107.
   PubMedGoogle Scholar
• Bower M, Powles T, Williams S, et al. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med. 2007;147:836–839.
   PubMed Web of Science ®Google Scholar
• Gerard L, Berezne A, Galicier L, et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman’s disease: ANRS 117 CastlemaB Trial. J Clin Oncol. 2007;25:3350–3356.
   PubMed Web of Science ®Google Scholar
• Marcelin AG, Aaron L, Mateus C, et al. Rituximab therapy for HIV-associated Castleman disease. Blood. 2003;102:2786–2788.
   PubMed Web of Science ®Google Scholar
• Bestawros A, Michel R, Seguin C, et al. Multicentric Castleman’s disease treated with combination chemotherapy and rituximab in four HIV-positive men: a case series. Am J Hematol. 2008;83:508–511.
   PubMed Web of Science ®Google Scholar
• Schmidt SM, Raible A, Kortum F, et al. Successful treatment of multicentric Castleman’s disease with combined immunochemotherapy in an AIDS patient with multiorgan failure. Leukemia. 2008;22:1782–1785.
   PubMed Web of Science ®Google Scholar
• Uldrick TS, Polizzotto MN, Aleman K, et al. Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease. Blood. 2014;124:3544–3552.
   PubMed Web of Science ®Google Scholar
• Gerard L, Michot JM, Burcheri S, et al. Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease. Blood. 2012;119:2228–2233.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106:2627–2632.
   PubMed Web of Science ®Google Scholar
• Van Rhee F, Fayad L, Voorhees P, et al. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman’s disease. J Clin Oncol. 2010;28:3701–3708.
   PubMed Web of Science ®Google Scholar
• Klass CM, Offermann MK. Targeting human herpesvirus-8 for treatment of Kaposi’s sarcoma and primary effusion lymphoma. Curr Opin Oncol. 2005;17:447–455.
   PubMed Web of Science ®Google Scholar
• Uldrick TS, Polizzotto MN, Aleman K, et al. High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy. Blood. 2011;117:6977–6986.
   PubMed Web of Science ®Google Scholar
• Millett GA, Peterson JL, Flores SA, et al. Comparisons of disparities and risks of HIV infection in black and other men who have sex with men in Canada, UK, and USA: a meta-analysis. Lancet. 2012;380:341–348.
   PubMed Web of Science ®Google Scholar
• Manzardo C, Esteve A, Ortega N, et al. Optimal timing for initiation of highly active antiretroviral therapy in treatment-naive human immunodeficiency virus-1-infected individuals presenting with AIDS-defining diseases: the experience of the PISCIS Cohort. Clin Microbiol Infect. 2013;19:646–653.
   PubMed Web of Science ®Google Scholar
• Shao HJ, Crump JA, Ramadhani HO, et al. Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania. AIDS Res Hum Retroviruses. 2009;25:1277–1285.
   PubMed Web of Science ®Google Scholar
• Sinha S, Shekhar RC, Singh G, et al. Early versus delayed initiation of antiretroviral therapy for Indian HIV-Infected individuals with tuberculosis on antituberculosis treatment. BMC Infect Dis. 2012;12:168.
   PubMed Web of Science ®Google Scholar
• Cingolani A, Torti L, Pinnetti C, et al. Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin’s lymphoma. Aids. 2010;24:2408–2412.
   PubMed Web of Science ®Google Scholar
• Ezzat HM, Cheung MC, Hicks LK, et al. Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma. Leuk Lymphoma. 2012;53:2390–2396.
   PubMed Web of Science ®Google Scholar
• Hentrich M, Hoffmann C, Mosthaf F, et al. Therapy of HIV-associated lymphoma-recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNA), in cooperation with the German AIDS Society (DAIG). Ann Hematol. 2014;93:913–921.
   PubMed Web of Science ®Google Scholar
• El-Sadr WM, Lundgren J, et al., Strategies for Management of Antiretroviral Therapy Study G. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283–2296.
   PubMed Web of Science ®Google Scholar